Search results

Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults

Type

Technology appraisal guidance

Published

18 May 2022

This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.

Type

NICE guideline

Published

17 May 2022

Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults

Type

Technology appraisal guidance

Published

11 May 2022

Evidence-based recommendations on tucatinib (TUKYSA) for HER2 positive locally advanced or metastatic breast cancer in adults after 2 or more anti HER2 treatment therapies

Type

Technology appraisal guidance

Published

27 April 2022

Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable

Type

Technology appraisal guidance

Published

27 April 2022

Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults

Type

Technology appraisal guidance

Published

20 April 2022

NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission. We will review this decision if the company decides to make a submission

Type

Technology appraisal guidance

Published

20 April 2022

Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults

Type

Technology appraisal guidance

Published

13 April 2022

NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care. We will review this decision if a stakeholder notifies NICE again of the topic

Type

Diagnostics guidance

Published

30 March 2022

Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

30 March 2022

NICE is unable to make a recommendation on tagraxofusp (Elzonris) for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics did not provide an evidence submission

Type

Technology appraisal guidance

Published

30 March 2022

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults

Type

Technology appraisal guidance

Published

24 March 2022

Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy

Type

Technology appraisal guidance

Published

16 March 2022

This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

Type

NICE guideline

Published

16 March 2022

Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults

Type

Technology appraisal guidance

Published

09 March 2022

Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor

Type

Technology appraisal guidance

Published

09 March 2022

NICE is unable to make a recommendation on lenalidomide (Revlimid) for treating relapsed or refractory mantle cell lymphoma. This is because Celgene did not provide an evidence submission. We will review this decision if the company decides to make a submission

Type

Technology appraisal guidance

Published

09 March 2022

Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults

Type

Technology appraisal guidance

Published

09 March 2022

Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults

Type

Technology appraisal guidance

Published

09 March 2022

Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults

Type

Technology appraisal guidance

Published

09 March 2022

This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.

Type

NICE guideline

Published

02 March 2022

Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies

Type

Technology appraisal guidance

Published

23 February 2022

Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules

Type

Diagnostics guidance

Published

23 February 2022

Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease

Type

Diagnostics guidance

Published

23 February 2022